Tim Connolly is the CEO of Corporate Strategies, LLC and thrives on solving difficult business problems others find impossible to fix. For over 30 years under his leadership, Corporate Strategies has created successful financial outcomes out of business crisis, litigation resolution and growth opportunities for a broad portfolio of businesses.
Victim: Elon Musk
Victim - Individual
Elon Reeve Musk is a South African-born American entrepreneur and businessman who founded X.com in 1999 (which later became PayPal), SpaceX in 2002 and Tesla Motors in 2003. Musk became a multimillionaire in his late 20s when he sold his start-up company, Zip2, to a division of Compaq Computers.
Investor: Warren Buffett
Investor
Warren Buffett is as the “Oracle of Omaha,” and he is one of the most successful investors of all time. Buffett runs Berkshire Hathaway, which owns more than 60 companies, including insurer Geico, battery maker Duracell and restaurant chain Dairy Queen. Mr. Buffett is the son of a U.S. congressman, he first bought stock at age 11 and first filed taxes at age 13. He pledges to give away most of his fortune. Last year (2019) he donated $3.6 billion, much of it to the foundation of friends Bill and Melinda Gates.
Article: Famed short-seller David Einhorn calls out Tesla’s billing practices again, erasing the stock’s post-earnings gain
Article - MediaBusiness Insider, 30 April 2020
David Einhorn of Greenlight Capital has again taken to Twitter to call out Tesla’s accounting practices in a message directed at CEO Elon Musk.
“Dear Elon, I guess the offer of a factory tour was never serious,” Einhorn, a long-time Tesla bear and short-seller, tweeted Thursday. “I remain curious about your accounts receivable.”
Shares of Tesla pared gains from earlier in the day and traded down as much as 3% following Einhorn’s comments.
Media: C. Austin (Bud) Burrell
Media
C. Austin (Bud) Burrell is a corporate finance generalist with over 30 years of Wall Street and related experience. He was a senior derivatives specialist and development stage company investment banker for more than 35 years on Wall Street.He is a 1968 Graduate of the U.S. Military Academy and a graduate of the Army’s Finance Officer Advanced Course.
Victim: Dr. Patrick M. Byrne
Victim - Individual
Dr. Patrick M. Byrne received a bachelor’s degree in philosophy and Asian studies from Dartmouth College, a master’s in philosophy (ethics) from Cambridge University as a Marshall Scholar, and a doctorate in philosophy (focusing on political theory, jurisprudence, and economics) from Stanford University. Patrick served as chairman, president and CEO of Centricut, LLC, a manufacturer of industrial torch consumables, then held the same three positions at Fechheimer Brothers, Inc., a Berkshire Hathaway company that manufactures police, firefighter and military uniforms. Patrick Michael Byrne is the former CEO of Overstock.com, Inc., a Utah-based internet retailer that has been publicly traded since 2002.
Official: Carl T. Hagberg
Official
Carl T. Hagberg is the chairman and CEO of Carl T. Hagberg & Associates. The company was formed in January, 2014 to separate our fast-growing business of providing highly qualified Independent Inspectors of Election from our consulting and publishing businesses. The company publishes The Shareholder Service OPTIMIZER − a quarterly newsletter that helps readers to understand and implement “best practices” in a fast-changing environment − and to get the most value possible out of their investor relations and shareholder servicing budgets.
Victim: Rodney Young
Victim - IndividualRodney Young is the CEO/President of Eagletech Communications, Inc. Eagletech manufactured and marketed telephone systems for small businesses. The company was a victim of naked short selling, which resulted in their ultimate downfall because of its inability to raise funds due to naked short selling.
Victim: Rick Smith
Victim - Individual
Rick Smith, founded Axon Enterprise (formerly TASER International) in 1993. As the TASER device became ubiquitous in law enforcement, Smith pushed the company beyond weapons technology and toward a broader purpose of using hardware, software, and artificial intelligence to make the world a safer place. Smith graduated from Harvard with a BA in biology and later earned a master’s in international finance from the University of Leuven in Belgium and an MBA from the University of Chicago.
Article: Co-Diagnostics Inc. [CODX] stock Reiterated by H.C. Wainwright analyst, price target now $20
Article - MediaCo-Diagnostics Inc. [CODX] stock Reiterated by H.C. Wainwright analyst, price target now $20
Brandon Evans
DBT News, 30 April 2020
Co-Diagnostics Inc. [NASDAQ: CODX] traded at a low on 04/29/20, posting a -8.57 loss after which it closed the day’ session at $12.37. The results of the trading session contributed to over 5099148 shares changing hands. Over the past one week, the price volatility of Co-Diagnostics Inc. stands at 10.98% while the volatility over the past one month is 12.61%.
The market cap for CODX stock reached $332.63 million, with 26.89 million shares outstanding and 20.80 million shares in the current float. Compared to the average trading volume of 12.82M shares, CODX reached a trading volume of 5099148 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Comment: This company is at risk of collusion between a placement agent and naked short sellers.
RELATED:
Data Guru: David E. Wenger
Data Guru
David E. Wenger is the President and Chief Executive Officer and founded Shareholder Intelligence Services, LLC (ShareIntel) in 2003. During his career on Wall Street, Mr. Wenger has been involved in numerous transactions involving investment banking, private equity financing, portfolio management, retail and institutional sales. Mr. Wenger was a founder and shareholder of Auerbach Financial Group, Inc. and Auerbach Pollak & Richardson, Inc. In this capacity, he was responsible for the strategic development and growth of the firm and he led and managed the firm’s Private Equity Group. Previously, Mr. Wenger was associated with a number of global financial firms and investment banks, including PaineWebber, Inc., Lehman Brothers and Drexel Burnham Lambert, where he focused primarily on client service, training, and new business development.
Article: H.C. Wainwright Keeps Their Hold Rating on PDS Biotechnology (PDSB)
Article - MediaH.C. Wainwright Keeps Their Hold Rating on PDS Biotechnology (PDSB)
Ryan Adist
SmarterAnalyst, 30 April 2020
H.C. Wainwright analyst Joseph Pantginis maintained a Hold rating on PDS Biotechnology (PDSB) today. The company’s shares closed last Wednesday at $0.95, close to its 52-week low of $0.62.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 14.5% and a 43.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.
Comment: This company is at risk of collusion between a placement agent and naked short sellers.
Article: Vertex Pharmaceuticals (VRTX) Receives a Buy from H.C. Wainwright
Article - MediaVertex Pharmaceuticals (VRTX) Receives a Buy from H.C. Wainwright
Austin Angelo
SmarterAnalyst, 30 April 2020
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (), with a price target of $295.00. The company’s shares closed last Wednesday at $251.05.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 8.9% and a 48.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Proteostasis Therapeutics.
Comment: This company is at risk of collusion between a placement agent and naked short sellers.
Article: H.C. Wainwright Keeps a Buy Rating on Aravive (ARAV)
Article - MediaH.C. Wainwright Keeps a Buy Rating on Aravive (ARAV)
Austin Angelo
SmarterAnalyst, 30 April 2020
In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Aravive (ARAV), with a price target of $15.00. The company’s shares closed last Thursday at $12.95.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 14.5% and a 43.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.
Comment: This company is at risk of collusion between a placement agent and naked short sellers.
Release: Rio2 Retains BUYINS.NET to Surveil Short Sellers and Market Makers
ReleaseRio2 Retains BUYINS.NET to Surveil Short Sellers and Market Makers
- Approximately 10 Million Total Shares Shorted in US Since March 2019
- Approximately 35 Million Total Shares Shorted in Canada Since March 2019
VANCOUVER, British Columbia, April 30, 2020 (GLOBE NEWSWIRE) — Rio2 Limited (“Rio2” or the “Company”) (TSXV: RIO; OTCQX: RIOFF; BVL: RIO) today announces that it has retained BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance.
Continue reading “Release: Rio2 Retains BUYINS.NET to Surveil Short Sellers and Market Makers”
